Key Points
- COO David Novack sold 30,000 shares on Dec. 24 at $15.49 each for $464,700, trimming his stake by 21.21% to 111,451 shares valued at about $1.73 million.
- Shares trade near their 1‑year high (opened $15.37; 1‑year high $15.49) with a market cap of ~$1.8 billion; the company beat Q3 EPS and revenue estimates but still reported a negative net margin of 13.13%.
- Analyst sentiment is mixed (average rating: Hold, consensus target $24.33) and institutional investors own roughly 96.96% of the stock.
Dynavax Technologies Corporation (NASDAQ:DVAX - Get Free Report) COO David Novack sold 30,000 shares of the business's stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $15.49, for a total value of $464,700.00. Following the transaction, the chief operating officer directly owned 111,451 shares of the company's stock, valued at $1,726,375.99. The trade was a 21.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Dynavax Technologies Trading Down 0.1%
Shares of DVAX opened at $15.37 on Tuesday. Dynavax Technologies Corporation has a 1-year low of $9.20 and a 1-year high of $15.49. The company has a market capitalization of $1.80 billion, a P/E ratio of -41.54 and a beta of 0.88. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The firm's 50 day simple moving average is $11.21 and its 200 day simple moving average is $10.62.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.07. The business had revenue of $94.88 million during the quarter, compared to analysts' expectations of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. Sell-side analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of DVAX. Hantz Financial Services Inc. lifted its stake in shares of Dynavax Technologies by 236.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 2,710 shares during the last quarter. LSV Asset Management purchased a new position in Dynavax Technologies in the 3rd quarter worth approximately $89,000. Osaic Holdings Inc. lifted its position in Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 1,226 shares during the last quarter. Callan Family Office LLC bought a new stake in Dynavax Technologies in the second quarter valued at approximately $107,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Dynavax Technologies during the third quarter valued at approximately $109,000. Hedge funds and other institutional investors own 96.96% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Wall Street Zen upgraded Dynavax Technologies from a "buy" rating to a "strong-buy" rating in a research report on Saturday. William Blair cut Dynavax Technologies from an "outperform" rating to a "hold" rating in a report on Wednesday, December 24th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Dynavax Technologies has an average rating of "Hold" and a consensus target price of $24.33.
Get Our Latest Report on DVAX
Dynavax Technologies Company Profile
(
Get Free Report)
Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.
Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
